Supplements

In this pilot trial, vitamin C supplementation raised plasma vitamin C levels in adults receiving donor stem cell transplants. Trends toward less acute graft-versus-host disease and milder or shorter oral mucositis were not statistically significant. Correcting the blood measurement therefore did not establish better clinical recovery, and larger trials are needed.

Keep in mind: The trial was small, and the abstract provides no confidence intervals for complication differences. No significant adverse events were reported, which cannot establish safety across larger or different patient groups.

The supplement affected blood fatty acid content and several inflammation-related responses to exercise, but the trial did not detect a significant improvement in anaerobic performance. Changes in laboratory markers therefore did not establish a performance benefit in these active young men. The abstract also leaves the size and direction of the individual biomarker effects unclear.

Keep in mind: The study was small and brief. The abstract reports significant biomarker interactions without numerical estimates or directions, preventing a clear judgment about their magnitude or practical meaning.

The review reported better working memory with the higher Brahmi dose category than with placebo and other extract groups. These were network estimates, with no direct Brahmi-versus-Ginkgo trials reported. Attention and processing speed did not show significant differences. These cognitive test results do not establish benefits for daily functioning.

Keep in mind: The lack of direct Brahmi–Ginkgo comparisons limits confidence in their relative effects. The abstract does not report trial durations or adverse-event results.

The review reports that daily vitamin D supplementation maintained adequate blood vitamin D levels in most healthy, term infants. That biochemical outcome is more clearly supported than proposed immune or respiratory benefits. The abstract does not establish a universally superior higher dose, and its conclusions leave benefits beyond infancy uncertain.

Keep in mind: This abstract-based account lacks study counts, pooled effect estimates and a defined follow-up period. The authors also report variation in methods, starting vitamin D status and adherence that complicates comparisons.

The review reported better offspring memory retention and higher levels of BDNF after maternal omega-3 supplementation in preclinical studies. Effects appeared stronger when offspring had experienced prenatal adversity. These findings can help frame future research questions, but they cannot show that supplementation improves children's development or establish its safety and effectiveness during human pregnancy.

Keep in mind: The abstract does not specify species, control conditions, or offspring assessment ages. Findings on oxidative stress and inflammation were heterogeneous, and the evidence summarized here is preclinical.

Oral nicotinamide riboside and nicotinamide mononucleotide consistently changed NAD-related metabolites in human studies, but this did not translate into consistent improvements in health or function. The review found clinical benefits for anti-aging or wellness remained uncertain. It also found no eligible trials testing wellness outcomes from intravenous or intramuscular NAD itself.

Keep in mind: Human outcomes differed across studies, and follow-up generally lasted weeks to months. The abstract provides no pooled clinical effect estimate or evidence of long-term effectiveness.

The pooled trials reported lower stress, anxiety and depression scores with ashwagandha supplementation. However, the abstract does not identify control treatments, participant diagnoses or intervention lengths, which limits interpretation of those results. The authors also describe variation across studies and call for stronger trials before translating the findings into clinical recommendations.

Keep in mind: The authors flag heterogeneity across trials. The abstract omits adverse-event findings and details needed to assess applicability to particular patients, so benefits and safety cannot be assessed fully from this record.

Lactoferrin altered some laboratory immune responses, but a measured antiviral signaling response did not differ between groups. Blood inflammation markers were lower with the higher dose than with the lower dose, without a corresponding difference from placebo. These findings do not establish that either dose prevents infection or improves health.

Keep in mind: The abstract reports laboratory markers over a short intervention, without reporting respiratory infection rates, illness severity or other clinical benefits. Changes in these markers cannot establish protection from infection.

Alpha-lipoic acid may ease symptoms in people with diabetic neuropathy, according to this review. Tingling, numbness, and pain-related scores improved. Selected nerve measurements and a blood sugar marker did not change significantly, so the findings do not establish nerve recovery or better blood sugar control. The abstract does not show how long improvements lasted.

Keep in mind: This abstract-based assessment lacks follow-up lengths, participant totals, and detailed adverse-event results, limiting judgments about durability and safety.

Supplementation did not significantly reduce total, nonvertebral or hip fractures in these generally healthy adults. A small change in whole-body bone density appeared in the measurement subgroup, while the other reported bone measures showed no clear benefit. That isolated density finding should not be treated as evidence that supplements prevented broken bones.

Keep in mind: The abstract describes participants not selected for low bone density or previous fractures; effects in higher-risk groups remain uncertain. Bone imaging involved only a subgroup.

The pooled evidence favored melatonin for reducing delirium occurrence in critically ill adults. It did not show statistically significant benefits for delirium duration, time in intensive care or survival. These results concern a specific hospital population and do not establish benefits for everyday sleep or supplement use.

Keep in mind: The abstract omits doses, follow-up periods and separate ramelteon results. Differences between trials and uncertainty around other outcomes limit interpretation.

The tested ginger extract produced statistically significant improvements in body fat measures compared with placebo over the study period. The abstract does not give the amount of fat lost or the size of the difference between groups. Its findings therefore support a specific short-term trial result, without establishing how noticeable the changes would be.

Keep in mind: Effect sizes and confidence intervals are missing from the abstract. The short follow-up also limits this abstract-based account of sustained benefit and safety.

The pooled trials reported small, statistically significant reductions in stress and anxiety with bovine milk fat globule membrane supplementation. Depression findings were not statistically significant. This suggests a limited signal for some psychological outcomes, but the abstract cannot show how noticeable the changes were, how long they lasted or who might benefit.

Keep in mind: Only 3 trials were included, limiting interpretation of publication bias. This abstract-based summary lacks numerical effect estimates, confidence intervals, doses and treatment durations for judging the practical meaning of the results.

The celery seed group had lower blood pressure and several blood-marker measurements at the end of the trial than at baseline. Insulin sensitivity and insulin secretion did not show statistically significant changes. Because the abstract does not present the corresponding placebo comparisons, these results cannot establish that celery seed caused the improvements.

Keep in mind: Although placebo controlled, the trial's abstract lists within-group changes without between-group estimates or confidence intervals. That limits what this abstract-based summary can conclude about efficacy.

The review reports favorable changes in markers of inflammation, oxidative stress and antioxidant capacity after astaxanthin supplementation. It also describes outcomes in studies combining the supplement with exercise and in selected clinical groups. The abstract does not show how large these changes were or establish broad clinical benefits from astaxanthin alone.

Keep in mind: This abstract-based summary lacks study-level designs, participant totals, doses, comparators and effect estimates. Safety results are not described. These omissions limit assessment of how convincing, clinically meaningful or broadly applicable the reported findings are.

Citrulline, given directly or through watermelon products, showed a possible blood pressure signal in postmenopausal women with hypertension. Results for arterial stiffness and blood-vessel function were inconsistent, and metabolic measures showed no consistent changes. These short studies leave uncertainty about broader benefits and do not support treating the supplement as an established therapy.

Keep in mind: Differences in study designs and outcomes prevented a pooled analysis. The abstract does not describe individual control conditions, and all trials were conducted in the United States over short periods.

The trial found larger reductions in selected inflammatory blood markers with the lowest fish-oil dose than with control. It did not find significant between-group differences in the other measured vascular markers. These laboratory findings do not demonstrate fewer cardiovascular events, and they do not establish that the lowest dose works better than higher doses.

Keep in mind: This abstract-based assessment is limited to blood markers over a short trial. Direct dose-to-dose effect estimates and confidence intervals are not provided, so a preferred dose cannot be established.

Among women with postmenopausal osteoporosis receiving zoledronate, added magnesium was not accompanied by statistically significant improvement from pretreatment levels in pain or the other measured outcomes. This small pilot study does not establish that magnesium has no effect, and the abstract does not provide a clear estimate of the difference between randomized groups.

Keep in mind: Only 35 women completed the analysis. The abstract reports baseline comparisons without numerical estimates of between-group treatment effects, limiting assessment of the size and precision of any possible benefit.

The trials found a reduction in the measured amount of Lp-PLA2 with omega-3 supplementation, but the activity result was statistically inconclusive. These are separate laboratory outcomes. This abstract therefore supports a finding about a blood marker; it does not show that participants had fewer heart attacks or other cardiovascular events.

Keep in mind: The abstract does not describe participant characteristics, treatment durations, or comparison treatments. Its laboratory endpoints cannot establish the clinical significance of the observed change in marker amount.

The supplement did not show a statistically significant advantage over the control for muscle mass or handgrip strength. Some other measurements improved from baseline within the supplement group, but those changes answer a different question. This small pilot study leaves uncertainty about benefits for people with cirrhosis and sarcopenia.

Keep in mind: Only 21 patients were enrolled. The abstract supplies no between-group effect estimates or confidence intervals, so the nonsignificant findings cannot establish equivalence or exclude an effect.

Adding amino acid supplements to resistance training may improve handgrip strength and physical performance in older adults with sarcopenia. The review found no statistically clear improvement in muscle mass measures. Because the evidence was rated low to very low certainty, substantial uncertainty remains about how much extra benefit the supplements provide.

Keep in mind: The evidence was rated low to very low certainty. The abstract omits treatment durations and does not describe adverse effects, limiting interpretation of benefits and harms.

The trials found faster conduction in selected nerves, while nerve-signal amplitude and a blood-sugar measure did not show clear changes. The abstract does not establish relief of pain, improved walking or better quality of life. These findings concern electrical nerve tests, so their everyday clinical importance remains uncertain.

Keep in mind: Vitamin E forms, doses and treatment lengths differed, and sample sizes were modest. The abstract does not supply symptom or functional benefit estimates, so electrical changes cannot establish meaningful daily-life improvement.

Adding high-dose vitamin D to standard nutrition was associated with lower illness-severity scores, shorter ventilation and ICU stays, and lower mortality in this trial. The participants had a specific sequence of severe injury and complications. These findings do not establish benefits for other ICU patients or support conclusions about routine supplementation outside this setting.

Keep in mind: The abstract does not report confidence intervals, adverse events or the size of the ventilation and ICU-stay differences. Follow-up was brief, limiting conclusions about later recovery.

In a selected middle-to-upper vitamin A subgroup, patients assigned vitamin D had better relapse-free survival than those assigned placebo. No benefit was detected in the lower or highest vitamin A ranges. Because researchers explored multiple cutoffs and grouped patients after the fact, this is a hypothesis about treatment differences, not an established way to choose supplementation.

Keep in mind: The abstract describes several vitamin A cutoff schemes, with final groupings chosen post hoc. This makes the subgroup result exploratory and in need of confirmation.